BARNSTABLE, MA--(Marketwired - Sep 23, 2013) - UV Flu Technologies, Inc. (
"The problem is getting worse, not better," said Jack Lennon, President of UV Flu Technologies, the manufacturer of the ViraTech UV-400, an FDA cleared air purifier which kills over 99% of airborne bacteria with every pass. "The risks are particularly acute for children under the age of four, seniors, or anyone having medical procedures such as cancer patients, where the immune-response system is compromised, or patients undergoing surgery or organ transplants, where the risk of infection could have serious consequences."
"The average person breathes 3,600 gallons of air per day, and little if any has been treated to kill or trap the airborne infection and contaminants that enter our lungs every minute we're alive. TB, Whooping Cough, MRSA, Staph, and a host of other airborne bacteria and viruses are growing stronger, in some cases becoming totally resistant to treatment with antibiotics. Many of these strains are at epidemic proportions in other countries, and it's only a matter of time before they spread to this country," said Mr. Lennon.
"Preventing the spread of these airborne infections is the first line of defense. Hospitals are now mandated to address the spread of HAI's, or Hospital Associated Infections, which is estimated to cause the death of as many as 99,000 patients per year. While it is important to disinfect surfaces where bacteria can spread, it is just as important to reduce the threat of breathing contaminated air," said Mr. Lennon.
"Maintaining clean air in the home, the workplace, and our schools, is as important as in the hospitals. Indoor air pollution has been found to impact sleep-disorders, and has been linked to higher risks of cancer, stroke, asthma, allergies and obesity. The next pandemic will probably be airborne. Investing in high-quality air purification is the best investment that can be made to protect family members, employees or patients."
Dr. Walter Kowalski, one of the worlds' leading authorities on ultraviolet light, and its ability in killing organic contaminants, in a report issued in June 2013, evaluated the ViraTech UV-400 Portable Air Purification Unit, and how effective it was in utilizing 3 UV lamps and a catalytic kill chamber, with the purpose of stopping the spread of airborne infection. After evaluating dozens of competing units, Dr. Kowalski said, "Considering the ability of the UV-400 to kill all bacteria, viruses, and fungal spores in a typical sized room, it is clearly among the 'Best in Class' of all devices evaluated."
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com, and click on the 5 minute video describing the ViraTech UV-400™.
About UV Flu Technologies, Inc. (
UV Flu Technologies is an innovative developer, manufacturer and distributor of biotechnology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector ($7 billion in 2011). The Company manufactures the ViraTech UV-400™, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com
About RxAir Industries, LLC
RxAir™ is the leading provider of air purification solutions for the medical industry with hundreds of units in waiting rooms to emergency rooms in respected medical facilities nationwide. RxAir™ products remove harmful pathogens from the air in infectious environments for emergency pandemics through isolation rooms and negative pressure rooms. The RxAir™ air purification line is 99.97% efficient, portable, and adaptable, requires zero-maintenance. http://www.rxair.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. Executing the transaction requires further work on structure, management, governance, and other significant matters. Within the next number of months, UV Flu's and RxAir's management will develop detailed plans for the Board's further consideration and final approval.
The completion of the spin-off is subject to a number of conditions, including final approval of the transaction by each Board, favorable tax rulings and or opinions of the transaction to UV Flu and to its shareholders, further due diligence as appropriate, and the filing and effectiveness of appropriate filings with the Securities and Exchange Commission ("SEC"). There can be no assurances given that the separation of UV Flu's business as described in this announcement will occur. UV Flu will provide interim updates as appropriate.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President/CEO
- Health Care Industry
Toll-Free: 1-877-358-5545 (FLU-KILL)
Retail or Internet Inquires:
Please call our Corporate Office at: 508-362-5455